Table 1.
Efficacy and functional affinity of CP55940, ∆9‐THC, and other SCRAs
| Compound | Operational efficacy τ | Functional affinity pK A (±SEM) | |
|---|---|---|---|
| Control (±SEM) | AM6544‐treated (±SEM) | ||
| CP55940 | 72 (30) | 7 (3) | 5.78 (0.09) |
| WIN55212‐2 | 57 (41) | 3 (1) | 4.84 (0.24) |
| ∆9‐THC | 0.9 (0.1) | 0.3 (0.1) | 6.54 (0.07) |
| 2‐AG | 60 (27) | 3 (1) | 5.16 (0.08) |
| AEA | 5 (2) | 2 (2) | 5.17 (0.10) |
| JWH‐018 | 43 (21) | 2.5 (1) | 5.72 (0.21) |
| AM‐2201 | 32 (6) | 2 (0.4) | 6.53 (0.08) |
| UR‐144 | 36 (7) | 3 (0.5) | 4.51 (0.15) |
| XLR‐11 | 152 (73) | 13 (9) | 4.68 (0.26) |
| PB‐22 | 44 (10) | 3.2 (1) | 6.73 (0.10) |
| 5F‐PB‐22 | 102 (48) | 7 (5) | 7.05 (0.09) |
| AB‐CHMINACA | 92 (42) | 4 (1) | 6.98 (0.12) |
| AB‐PINACA | 28 (7) | 2 (0.4) | 6.90 (0.21) |
| MDMB‐CHMICA | 79 (32) | 8 (4) | 6.35 (0.17) |
| MDMB‐FUBINACA | 103 (62) | 5 (1.4) | 7.12 (0.10) |
| 5F‐MDMB‐PICA | 233 (65) | 14 (3) | 6.71 (0.13) |
| CUMYL‐4CN‐BINACA | 70 (28) | 4 (1) | 7.48 (0.07) |
Note. Values were calculated using the operational model of pharmacological agonism following CB1 receptor depletion with AM6544, as outlined in Section 2.